Vasvi Singh, MD
Cardiovascular Disease · Overland Park, KSNPI 1659652816
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $287,668 of the $405,275 with a category attached, or 71.0%. 26 manufacturers reported payments, led by AstraZeneca at 40.1% of the total. 2025 is the largest year on record at $240,301, more than ten times the $18,516 reported in 2020. Among cardiovascular disease clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 436 payments — averaging $929.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$163K
- Pfizer$139K
- Bridgebio Pharma, Inc.$73K
- Alnylam Pharmaceuticals Inc.$22K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$7K
- Amgen$302
- plus $2K from 20 others
Across 4 payments — averaging $7591.96 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$30K
What the payments were for
- Consulting fees$36,6789%
- Speaking & faculty fees$287,66871%
- Grants$18,4365%
- Travel & lodging$53,17613%
- Food & beverage$9,2292%
- Education$890%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 147 | $162,632 |
| Pfizer | 95 | $139,125 |
| Bridgebio Pharma, Inc. | 59 | $72,672 |
| Alnylam Pharmaceuticals Inc. | 30 | $22,230 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 32 | $6,551 |
| Amgen | 14 | $302 |
| GE HealthCare | 4 | $251 |
| Irhythm Technologies, Inc. | 11 | $246 |
| Boston Scientific | 3 | $192 |
| E.r. Squibb & Sons, L.L.C. | 3 | $144 |
| Boehringer Ingelheim | 8 | $133 |
| Heartflow, Inc. | 1 | $111 |
| Regeneron Healthcare Solutions, Inc. | 1 | $98 |
| Novo Nordisk | 4 | $84 |
| Astellas Pharma US Inc | 1 | $80 |
| Philips North America LLC | 4 | $64 |
| Novartis | 3 | $63 |
| Johnson & Johnson | 4 | $59 |
| Amarin Pharma, Inc. | 3 | $55 |
| Sanofi-aventis U.S. LLC | 3 | $54 |
| Lemaitre Vascular, Inc. | 1 | $43 |
| Tactile Systems Technology Inc | 1 | $24 |
| Bayer | 1 | $17 |
| Abbott | 1 | $17 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$405,275 in reported general payments places this provider in the 95th percentile of 175 cardiovascular disease providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 70 | $1,726,898 |
| EliquisApixaban | 12 | $16,724 |
| JardianceEmpagliflozin | 11 | $6,393 |
| Metoprolol Succinate | 52 | $671 |
| Atorvastatin Calcium | 55 | $481 |
| Losartan Potassium | 36 | $410 |
| Amlodipine Besylate | 43 | $202 |
| Ezetimibe | 18 | $195 |
| Spironolactone | 28 | $164 |
| Carvedilol | 17 | $158 |
| Furosemide | 25 | $109 |
| Rosuvastatin Calcium | 11 | $93 |
| Hydrochlorothiazide | 13 | $7 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $139,125 | $1,743,62282 claims |
| Boehringer IngelheimJardiance | $133 | $6,39311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 175 cardiovascular disease providers in Kansas.
Other cardiovascular disease in Overland Park
- Rachel SoslandOverland Park$33K
- Ahmed ElballatOverland Park$22K
- Paul NagerOverland Park$10K
- Ronnie SmallingOverland Park$9K
- van JonesOverland Park$7K
- Alan SchneiderOverland Park$6K
- Theodore PopeOverland Park$5K
- Stephen BloomOverland Park$5K
- James MarcumOverland Park$4K
- Bassem ChehabWichita$482K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.